OBJECTIVE: Breast cancer recurrence may be promoted by immunosuppression due to decreased immune surveillance. The aim of this study was to examine the rates of breast cancer recurrence in patients with immune-mediated disease and treated breast cancer who received therapy with methotrexate, thiopurines, or anti-tumor necrosis factor (anti-TNF). METHODS: Three retrospective cohort studies within Medicare (2000-2012) included women with rheumatoid arthritis (RA) or inflammatory bowel disease (IBD) who underwent surgery for primary breast cancer. Recurrent or second primary breast cancers occurring more than 365 days after the initial surgery were identified. Separate Cox regression models were used to examine the risk of cancer recurrence in patients treated with methotrexate, thiopurines, or anti-TNF agents after surgery, each compared with no use. Analyses were matched for type of breast surgery and receipt and type of adjuvant therapy. RESULTS: Across all medication groups, 107 women experienced breast cancer recurrence during 5,196 person-years. The incidence rates were 20.3 and 19.6 per 1,000 person-years in methotrexate users and nonusers, respectively, 32.3 and 17.6 in thiopurine users and nonusers, respectively, and 22.3 and 19.5 in anti-TNF users and nonusers, respectively. There was no significantly increased risk of breast cancer recurrence with use of methotrexate (adjusted hazard ratio [HR] 1.07, 95% confidence interval [95% CI] 0.67-1.69), anti-TNF therapy (HR 1.13, 95% CI 0.65-1.97), or thiopurines (HR 2.10, 95% CI 0.62-7.14). CONCLUSION: The risk of breast cancer recurrence in patients who received methotrexate, thiopurine, or anti-TNF therapy was not statistically significantly increased, although we cannot rule out a 2-fold or greater increased risk in those treated with thiopurines. These data provide reassurance to clinicians choosing to start methotrexate or anti-TNF therapy in RA or IBD patients with treated breast cancer.
OBJECTIVE:Breast cancer recurrence may be promoted by immunosuppression due to decreased immune surveillance. The aim of this study was to examine the rates of breast cancer recurrence in patients with immune-mediated disease and treated breast cancer who received therapy with methotrexate, thiopurines, or anti-tumor necrosis factor (anti-TNF). METHODS: Three retrospective cohort studies within Medicare (2000-2012) included women with rheumatoid arthritis (RA) or inflammatory bowel disease (IBD) who underwent surgery for primary breast cancer. Recurrent or second primary breast cancers occurring more than 365 days after the initial surgery were identified. Separate Cox regression models were used to examine the risk of cancer recurrence in patients treated with methotrexate, thiopurines, or anti-TNF agents after surgery, each compared with no use. Analyses were matched for type of breast surgery and receipt and type of adjuvant therapy. RESULTS: Across all medication groups, 107 women experienced breast cancer recurrence during 5,196 person-years. The incidence rates were 20.3 and 19.6 per 1,000 person-years in methotrexate users and nonusers, respectively, 32.3 and 17.6 in thiopurine users and nonusers, respectively, and 22.3 and 19.5 in anti-TNF users and nonusers, respectively. There was no significantly increased risk of breast cancer recurrence with use of methotrexate (adjusted hazard ratio [HR] 1.07, 95% confidence interval [95% CI] 0.67-1.69), anti-TNF therapy (HR 1.13, 95% CI 0.65-1.97), or thiopurines (HR 2.10, 95% CI 0.62-7.14). CONCLUSION: The risk of breast cancer recurrence in patients who received methotrexate, thiopurine, or anti-TNF therapy was not statistically significantly increased, although we cannot rule out a 2-fold or greater increased risk in those treated with thiopurines. These data provide reassurance to clinicians choosing to start methotrexate or anti-TNF therapy in RA or IBDpatients with treated breast cancer.
Authors: Lisa J Herrinton; Jeffrey R Curtis; Lang Chen; Liyan Liu; Elizabeth Delzell; James D Lewis; Daniel H Solomon; Marie R Griffin; Rita Ouellet-Hellstom; Timothy Beukelman; Carlos G Grijalva; Kevin Haynes; Bindee Kuriya; Joyce Lii; Ed Mitchel; Nivedita Patkar; Jeremy Rassen; Kevin L Winthrop; Parivash Nourjah; Kenneth G Saag Journal: Pharmacoepidemiol Drug Saf Date: 2011-09-15 Impact factor: 2.890
Authors: Jessica Chubak; Onchee Yu; Gaia Pocobelli; Lois Lamerato; Joe Webster; Marianne N Prout; Marianne Ulcickas Yood; William E Barlow; Diana S M Buist Journal: J Natl Cancer Inst Date: 2012-04-30 Impact factor: 13.506
Authors: Tim Bongartz; Alex J Sutton; Michael J Sweeting; Iain Buchan; Eric L Matteson; Victor Montori Journal: JAMA Date: 2006-05-17 Impact factor: 56.272
Authors: Jie Zhang; Fenglong Xie; Elizabeth Delzell; Lang Chen; Kevin L Winthrop; James D Lewis; Kenneth G Saag; John W Baddley; Jeffrey R Curtis Journal: JAMA Date: 2012-07-04 Impact factor: 56.272
Authors: Nynne Nyboe Andersen; Björn Pasternak; Saima Basit; Mikael Andersson; Henrik Svanström; Sarah Caspersen; Pia Munkholm; Anders Hviid; Tine Jess Journal: JAMA Date: 2014-06-18 Impact factor: 56.272
Authors: Rachelle Buchbinder; Melissa Barber; Louise Heuzenroeder; Anita E Wluka; Graham Giles; Stephen Hall; Andrew Harkness; Daniel Lewis; Geoff Littlejohn; Marian H Miller; Peter F J Ryan; Damien Jolley Journal: Arthritis Rheum Date: 2008-06-15
Authors: Ali M Abbas; Rawaa M Almukhtar; Edward V Loftus; Gary R Lichtenstein; Nabeel Khan Journal: Am J Gastroenterol Date: 2014-09-23 Impact factor: 10.864
Authors: Peter K K Wong; Hanish Bagga; Claire Barrett; Geoff Chong; Patrick Hanrahan; Teja Kodali; Mona Marabani; H Miles Prince; John Riordan; Phillip Swarbrick; Ray White; Laurel Young Journal: Curr Rheumatol Rep Date: 2018-09-01 Impact factor: 4.592